Alzheimer’s disease
APOE4 is associated with an increased risk of Alzheimer’s disease. A European consortium coordinated by the University of Geneva believes they have identified at least one mechanism of action.
The clinical trial, called SKYLINE, is starting without results from other key ongoing studies on the drug.
The FDA has not yet issued any hold orders to Cassava, but the company expects that its time is coming after rivals Denali and Cortexyme received theirs.
LEXEO Therapeutics has announced positive initial data from its Phase I/II trial of LX1001, a gene therapy intended for the treatment of APOE4 homozygous Alzheimer’s disease (AD).
First Moscow State Medical University has paused recruiting new patients for its ongoing clinical trials following a disruption in the university’s ability to receive clinical trial samples.
AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion.
Halberd has demonstrated it can control each of the top 10 antigens associated with various neurodegenerative diseases, including Alzheimer’s, Parkinson’s, epilepsy, TBI and PTSD.
CMS says it would only cover the cost of Biogen’s Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”
The planned testing for DNL919 was held back pending additional documentation required to initiate the studies and information on the preclinical toxicology assessment.
CMS issued a draft decision for Biogen’s Alzheimer’s drug and said it would only cover the cost of Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”
PRESS RELEASES